clinical trial · NCT06837142
A Drug-drug Interaction Study With TS-172 in Healthy Adult Male Subjects
Taisho Pharmaceutical Co., Ltd.·phase1·completed·n = 30
Healthy Male SubjectsTriazolam and TS-172TS-172 and itraconazole
brief summary
An open-label, single-center, single-sequence study to evaluate the drug-drud interaction between the CYP3A substrate triazolam and TS-172 (part A) and the potent CYP3A inhibitor itraconazole and TS-172 (part B) in healthy male subjects on their pharmacokinetics, safety and tolerability
started
Mar 11, 2025
primary completion
Apr 30, 2025
completion
Apr 30, 2025
last updated
May 15, 2025
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol